Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Mesterolone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1984

Randomised trial of mesterolone versus vitamin C for male infertility. Scottish Infertility Group.

A prospective randomised trial was carried out to assess the effect of 9 months' treatment with either mesterolone or vitamin C in 368 men complaining of an infertile marriage. There was no significant difference in the wife's pregnancy rate between the two treatment groups. A separate analysis of the data was made to include only men with a low normal testosterone (less than 16 nmol/l) and low sperm density (less than 10 million/ml). This separate analysis was also restricted to men married to wives with normal test results for tubal patency and ovulation and again there was no difference in pregnancy rates between the two treatment groups. These results indicate that mesterolone therapy given in the absence of any defined endocrinopathy is of no benefit in promoting male fertility and furthermore we have been unable to find any subgroup who will respond. Improvements in the therapy of male infertility are only likely after a diagnosis has been defined.

Ascorbic Acid↗
PubMed1975

[Androgenic treatment with depot mesterolone in dyspermia].

The clinical use of testosterone, and more recently of orally administered mesterolone in disorders of male fertility is of limited therapeutic efficacy, as shown by data found in the literature. On the basis of these considerations, the authors have tested mesterolone cyclopentylproprionate in 15 subjects suffering from sperm disorders. The drug, which is slowly released in the tissues has been parenterally administered at a total dose of 1,200 mg (100 mg per week). During the therapeutic trial the following aspects have been studied: spermiologic and hormonal patterns, general conditions, libido, principal organic functions and the possible side effects. Results are critically evaluated.

Adult↗
PubMed1976

[The effect of mesterolone in panmyelopathic anemia and anemia of renal failure].

A controlled randomized multicenter trial was carried out to examine the therapeutic value of the androgen mesterolone in aplastic anemia and anemia of renal failure. the drug was given in a dose of 2 mg/kg orally for 6 months. Control patients received no androgens but were otherwise similarily treated. 31 patients with aplastic anemia could be evaluated. No significant difference was found between androgen treated control cases in respect to bone marrow cellularity, improvement of peripheral blood cell counts or survival. In a group of 14 patients not being hemodialyzed with anemia from renal failure, 3 of the androgen treated and none of the control patients showed progressive and significant improvement of erythropoiesis; however, this was not a statistically significant difference when the both groups of patients were compared. The results do not suggest that the androgen mesterolone is of therapeutic value in the majority of adult patients with aplastic anemia. Possible reasons of the discrepancy to positive results reported in the literature are discussed.

Adolescent↗
PubMed2005

Microbial transformation of mesterolone.

The microbial transformation of mesterolone (= (1alpha,5alpha,17beta)-17-hydroxy-1-methylandrostan-3-one; 1), by a number of fungi yielded (1alpha,5alpha)-1-methylandrostane-3,17-dione (2), (1alpha,3beta,5alpha,17beta)-1-methylandrostane-3,17-diol (3), (5alpha)-1-methylandrost-1-ene-3,17-dione (4), (1alpha,5alpha,15alpha)-15-hydroxy-1-methylandrostane-3,17-dione (5), (1alpha,5alpha,6alpha,17beta)-6,17-dihydroxy-1-methylandrostan-3-one (6), (1alpha,5alpha,7alpha,17beta)-7,17-dihydroxy-1-methylandrostan-3-one (7), (1alpha,5alpha,11alpha,17beta)-11,17-dihydroxy-1-methylandrostan-3-one (8), (1alpha,5alpha,15alpha, 17beta)15,17-dihydroxy-1-methylandrostan-3-one (9), and (5alpha,15alpha,17beta)-15,17-dihydroxy-1-methylandrost-1-en-3-one (10). Metabolites 5-10 were found to be new compounds. All metabolites, except 2, 3, 6, and 7, exhibited potent anti-inflammatory activity. The structures of these metabolites were characterized on the basis of spectroscopic studies, and the structure of 5 was also determined by single-crystal X-ray-diffraction analysis.

Biotransformation↗
PubMedDate not supplied

Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.

A double-blind, randomized, group comparative study was performed in hypogonadal male patients in order to compare the effects on sexual activity and mental state of testosterone undecanoate (TU) and mesterolone (M). The TU-treated group contained 12 patients, and the M-treated group contained 14 patients. The variables of sexual activity and of mental state were scored an evaluated statistically by means of the nonparametric randomization test for 2 independent groups. TU induced a marked improvement of the sexual activity and of the mental state. After 4 weeks of treatment the effects were significantly better than in the M-treated group: libido (p less than 0.001), erections (p less than 0.01), ejaculations (p less than 0.05) and mental state (p less than 0.001).

Adult↗
PubMed1977

The hormone response to a synthetic androgen (mesterolone) in oligospermia.

Forty subfertile men with oligospermia were treated with a synthetic androgen (Mesterolone). The effect of the drug was evaluated by measuring serum testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and analysing the semen before and after treatment. The results demonstrated that in twenty-three patients treated for 6-9 months there was a significant decrease in serum testosterone (P less than 0.01); the means +/- SEM before and after treatment were 17.05 +/- 0.95 and 14.7 +/- 0.95 (nmol/l serum) respectively. There was a pronounced increase in serum LH (P less than 0.01), the values being 2.73 +/- 0.26 and 3.61 +/- 0.3 (u/l) respectively. However, no significant difference was found in serum FSH before and after treatment. The sperm concentration showed a variable response to treatment. In twenty-one patients there was either no change or worsening in the sperm concentration, whereas in nineteen patients an improvement was observed. The analysis of variance of sperm concentration and motility for the periods before and after treatment, for all the patients, showed no significant difference in the sperm concentration F1.145 = 2.82 (P=0.1).

Dihydrotestosterone↗
PubMedDate not supplied

The effects of mesterolone on the male accessory sex organs, on spermiogram, plasma testosterone and FSH.

42 subfertile male ambulatory patients were treated with Proviron. Moderate oligoastheno-teratozoospermia was the most common injury in sperm analysis. The treatment did not change the amount of plasma FSH, testosterone or prostate phosphatase. Acid phosphatase and citric acid of semen showed an increased activity with mesterolone treatment. The amount of fructose decreased, it is probably due to the increased number of spermatozoa, which need more fructose for their metabolism respectively. The sperm of 93% of the patients improved or stayed unchanged. 30% of the patients developed normozoospermia. 6 pregnancies were achieved.

Acid Phosphatase↗
PubMed1977

Combined mesterolon-clomiphene citrate therapy for treatment of oligospermia.

42 subfertile patients with normal levels of plasma testerone (26 subnormal, suffering from oligospermia) have been treated with a combination of clomiphene citrate (50 mg Clomid daily) and mesterolon (50 mg Proviron daily) over a period of at least 3-6 months. The treatment resulted in pregnancy in 6 cases and in a significant improvement of the sperm count in 16. In 7, however, whilst the sperm count improved the qualitative results were unsatisfactory as many sperms were immature. Restricted spermatogenesis and a sperm count below 5 million/ml must be considered unfavourable but does not constitute a counter-indication to the combined therapy. No hazardous complications were observed.

Cell Count↗
PubMed1983

[Treatment of fertility disturbances in the male with a combination of mesterolone and kallikrein].

73 males with different fertility disturbances (53 X oligozoospermia, 4 X asthenozoospermia and 16 X teratozoospermia) were treated by a combination of mesterolone (50 mg daily) and kallikrein (6 X 100 KU daily; every two hours one tablet); duration of treatment: three months. Before starting the treatment two semen analyses were performed; furthermore semen control at the end of the treatment as well as three and six months after ending the therapy. The sperm density don't demonstrate any changes. The normal morphology of the spermatozoa increased about 10%. In selected cases with a very bad sperm morphology a testicular biopsy were performed; in these cases the percentage of normal spermatozoa increased for about 21%. The motility rate showed no significant changes. It can be demonstrated that this combination don't better effects than other treatment. The best way is a treatment at a well selected material with a special drug for a special case.

Adult↗
PubMedDate not supplied

[The effect of a synthetic androgen (mesterolone) on semen quality].

224 infertile men were treated with mesterolone (M.;30, or 60 mg/die) for a minimum of three months. When comparing semen analyses done before and after treatment with M., a small but distinct reduction of hyperspermia as well as an augmentation of hypospermia were evident, an increase of sperm density in oligozoospermia grade I (20-40 kx 10(6) sperm/ml) was revealed, and an improvement of sperm motility in asthenozoospermia was seen. These was no change in sperm morphology. According to our data, careful selection of patients for treatment with M. Based on aetio-pathogenic considerations appears to be the "salient point" in the administration M. As a general rule, treatment with M. should be confined to patients with mild idiopathic oligo (astheno) zoospermia where no specific therapy - such as, e.g., high ligation for varicocele - is available.

Dihydrotestosterone↗